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Background: Mechanical loading of bones activates modeling and suppresses remodeling by promoting bone
formation. Eldecalcitol is approved for the treatment of osteoporosis in Japan and is often used in patients
undergoing exercise therapy. However, the effects of eldecalcitol on bone formation during mechanical loading
are unknown. The aim of this study was to clarify the influence of eldecalcitol administration on bone response
to mechanical loading using a four-point bending device.
Methods: Forty six-month-old female Wistar rats were randomized into four groups based on eldecalcitol dose
(vehicle administration (VEH), low dose (ED-L), medium dose (ED-M), and high dose (ED-H)). Loads of 38 N were
applied in vivo to the right tibia for 36 cycles at 2 Hz, by four-point bending, 3 days per week for 3 weeks. After
calcein double-labeling, rats were sacrificed and tibial cross sections were prepared from the region with maximal
bending at the central diaphysis. Histomorphometry was performed on the entire periosteal and endocortical
surface of the tibiae, dividing the periosteum into lateral and medial surfaces.
Results: The effects of external loading on bone formation parameters were significant at all three surfaces. Bone
formation parameters were highest in the ED-H group, and the effects of eldecalcitol on bone formation rate
were significant at the endocortical surface. In addition, the interaction between loading and eldecalcitol dose
significantly affected bone formation rate at the endocortical surface.
Conclusions: Eldecalcitol enhanced the cortical bone response to mechanical loading and a synergistic effect
was observed in a rat model.
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Eldecalcitol is a new vitamin D receptor ligand bearing a
hydroxypropyloxy substituent at the 2β position of
1α,25-dihydroxyvitamin D3 (calcitriol). While the bind-
ing affinity of eldecalcitol to the vitamin D receptor is
approximately half that of calcitriol, eldecalcitol binds to
serum vitamin D binding protein about four times stronger
than calcitriol [1].
In a randomized, placebo-controlled, double-blind
clinical trial in osteoporotic patients receiving vitamin
D supplementation, 12-month treatment with eldecalci-
tol increased lumbar and hip bone mineral density in a
dose-dependent manner, without causing sustained* Correspondence: hagino@med.tottori-u.ac.jp
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(http://creativecommons.org/publicdomain/zerohypercalcemia [2]. In a fracture prevention trial, 3-year
treatment with eldecalcitol reduced the incidence of
vertebral fractures to a significantly greater extent than
alfacalcidol, with a relative risk reduction of 26 % [3].
Eldecalcitol inhibits in vitro osteoclast formation
through suppression of c-Fos protein expression in osteo-
clast precursor cells. Vitamin D also suppresses the ex-
pression of nuclear factor of activated T cells c1 (NFATc1),
a key regulator of osteoclast formation, by upregulating
interferon-β (IFN-β) in osteoclasts [4]. Calcitriol inhibits
parathyroid hormone (PTH)-induced bone resorption
at physiological concentrations and stimulates bone re-
sorption at toxic doses in thyroparathyroidectomized
rats infused with PTH [5]. Based on these findings,
eldecalcitol acts mainly as an antiresorptive agent that
reduces osteoclast activity. Harada et al. recently
showed that eldecalcitol inhibits osteoclast maturations article distributed under the terms of the Creative Commons Attribution
s/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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oblasts on bone surfaces in vivo, suggesting that elde-
calcitol prevents bone resorption by affecting osteoblast
activity in vivo [6].
Supplementing these findings, a recent study using an
ovariectomized rat model showed that eldecalcitol in-
creased bone formation rate and bone volume, indicating
an anabolic effect [7]. Furthermore, histological examin-
ation of rat bones treated with eldecalcitol revealed that
simultaneous stimulation of differentiation and inhibition
of differentiation of osteoblastic cells impaired osteoblast–
osteoclast interaction on the bone surface [8].
Mechanical loading of bones activates modeling and
suppresses remodeling by promoting bone formation [9].
This process suggests the presence of bone mechanosen-
sors that can transduce mechanical stimuli into anabolic
or catabolic signals for bone tissue. Eldecalcitol is ap-
proved for the treatment of osteoporosis in Japan and is
often used in patients undergoing exercise therapy.
However, the effects of eldecalcitol on bone formation
during mechanical loading are unknown. The aim of this
study was to clarify the influence of eldecalcitol adminis-




Six-month-old female Wistar rats (retired breeder; Shimizu
Laboratory Supply, Kyoto, Japan), with initial body weights
ranging between 255 g and 355 g, were used in this study.
During the experimental period, water and commercially
available food (CE-2; CLEA Japan, Tokyo, Japan; calcium
content 1.18 g/100 g, phosphorus content 1.09 g/100 g,
vitamin D3 content 250 IU/100 g) were given ad libitum.
The duration of daily light exposure in the breeding room
was 12 h (7:00 AM to 7:00 PM), and the room temperature
was maintained at 24 °C.
After a 7-day acclimation period, rats were randomized
into four groups based on eldecalcitol dose (n = 10 per
group), each with the same mean body weight, as follows:
(1) vehicle administration (VEH), (2) low dose (ED-L), (3)
middle dose (ED-M), and (4) high dose (ED-H). Rats were
allowed normal cage activity between loading sessions.
Eldecalcitol administration
We prepared 0.025–0.1 μg/ml solutions of eldecalcitol
by dissolving in medium-chain triglyceride. Eldecalcitol
or vehicle (medium-chain triglyceride) was administered
orally via gastric lavage 3 days per week for 3 weeks.
The rats received vehicle alone (VEH) or eldecalcitol at
doses of 0.025 μg/kg (ED-L), 0.05 μg/kg (ED-M), or
0.1 μg/kg (ED-H). After administration of eldecalcitol or
vehicle, tibial mechanical loading was performed on the
same day.In vivo external mechanical loading
In vivo mechanical loading involved load application
using a four-point bending device (developed and assem-
bled in the Biomechanics Laboratory, Creighton Univer-
sity) [10, 11]. Each rat was anesthetized with ether, and
its right lower leg was placed between the pads of the
device. The right tibia was loaded at 38 N for 36 cycles
at 2 Hz, 3 days per week for 3 weeks, for a total of 9 days.
The left tibia was not loaded.
The force applied during loading was monitored by a
strain gauge attached to the lever arm as previously re-
ported [10–13]. Before the experiment, the four-point
bending device was calibrated with a load cell that had
been previously calibrated by application of forces ran-
ging from 0 to 70 N, using a mechanical testing machine
(MTS810; MTS, Minneapolis, MN, USA). The actual
applied load during in vivo four-point bending was calcu-
lated based on this calibration [10–13].
Bone histology
Rats received calcein injections (6 mg/kg BW, i.p.) on ex-
perimental days 13 and 19. On day 20, rats in all four
groups were anesthetized with 50 mg/kg BW ketamine
hydrochloride and 10 mg/kg BW xylazine, and were
sacrificed by exsanguination. Both loaded (right) and
non-loaded (left) tibiae were removed, placed in 10 %
phosphate-buffered formalin for 24 h, and then trans-
ferred to 70 % ethanol. The tibiae were cut into three
pieces: (a) the proximal 1 cm, (b) the distal 5 mm, and
(c) the remaining central diaphysis. Central regions
were stained with Villanueva bone stain for 72 h [11, 14].
Specimens were dehydrated with increasing concentra-
tions of ethanol and acetone and then embedded in me-
thyl methacrylate. The region of maximum bending was
located in the central diaphysis, 3–13 mm proximal to the
tibio-fibular junction (TFJ) [10–13]. Two cross-sections
were prepared from the region of maximum bending, spe-
cifically at 4 mm and 4.5 mm proximal to the TFJ. These
cross-sections were then ground to a thickness of 60 μm
and mounted on glass slides. Histomorphometric data
were collected from these two sections and mean values
were calculated.
Calculation of in vivo strain
The in vivo strain was calculated using the moment of
inertia of each central diaphyseal cross-section, as previ-
ously reported [11]. The outline of the cortical bone on
each slide was traced, and the moment of inertia and
section modulus for each cross-section were calculated
using Bone Histomorphometry Software (System Supply,
Nagano, Japan). The peak compressive strain on the
lateral surface was calculated using beam-bending theory:
Єc ¼ MC=EI; ð1Þ
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lateral periosteal surface, M = bending moment (N-m),
E = longitudinal Young’s modulus (estimated as 29 ×
109 N/m2), I = moment of inertia, and C = distance from
the centroid to the lateral surface.
The in vivo peak compressive strain (Єp) at the lateral
periosteal surface was then predicted from Єc using the
following formula:
Єp ¼ 0:828 Єc ‐ 127:16: ð2Þ
Equation (2) was derived from the in vivo strain gauge
measurement [10].
Histomorphometry
A camera connected to a personal computer was used to
run Bone Histomorphometry Software (System Supply
Co. Ltd.). The standard nomenclature for bone histo-
morphometry variables was used [15].
The total tissue area (TtT.Ar, mm2) and marrow area
(Ma.Ar, mm2) were measured, and the difference be-
tween them was reported as the cortical area (Ct.Ar,
mm2). The woven bone contained irregular collagen
bundles and a diffuse fluorochrome label, which was
identified under conventional polarized and ultraviolet
light. The Ct.Ar did not include the woven bone area
(Wo.Ar).
For both the periosteum and endosteum, we measured
the single-labeled perimeter (sL.Pm, %), double-labeled
perimeter (dL.Pm, %), and woven bone perimeter
(Wo.Pm, %; defined as the perimeter with overlying
woven bone). The Wo.Pm was not included in calcula-
tions of the sL.Pm or dL.Pm. The formation perimeter
(F.Pm) was defined as (dL.Pm +Wo.Pm + sL.Pm/2)/
B.Pm [14, 16, 17]. The mineral apposition rate (MAR;
μm/d) and surface-based bone formation rate (BFR;Fig. 1 Three surfaces of the tibia for histomorphometric analysis. The tibial
indicated for histomorphometric analysisμm3/μm2/d) were calculated. A minimum MAR value of
0.3 μm/d was used in rats showing only sL.Pm [18]. The
BFR was calculated using the formula BFR =MAR ×
F.Pm [13, 14, 16].
Histomorphometric data were collected from the peri-
osteal and endocortical surfaces of the tibia. The tibial
periosteal surface was subdivided into lateral and medial
surfaces in the same manner as in our previous studies
(Fig. 1) [14, 17, 19], because the type of stress applied by
the four-point bending device differed between the two
surfaces (compression vs. tension) [10].
Statistical analysis
Data were analyzed by repeated two-way analysis of vari-
ance (ANOVA) for the effects of external loading
(loaded and non-loaded) and eldecalcitol treatment, and
their interaction. Post hoc multiple comparisons among
eldecalcitol groups were performed using the Dunnett’s
test. SPSS Statistics software (version 21, SPSS Inc.,
Chicago, IL, USA) was used for the analyses and P < 0.05
was considered to be statistically significant.
Animal ethics
Our procedures were approved by the Committee on




One rat each in the ED-H, ED-L, and VEH groups died
during the loading as a result of ether anesthesia. The
average initial body weights were 295.7 ± 14.5 g, 293.5 ±
18.6 g, 285.0 ± 8.2 g, and 284.0 ± 15.2 g for the ED-H,
ED-M, ED-L, and VEH groups, respectively. The final
body weights were 271.5 ± 13.6 g, 275.5 ± 21.0 g, 280.0 ±
18.5 g, and 276.1 ± 10.5 g, respectively. There were noperiosteal surface was divided into lateral and medial regions as
Table 1 Applied force and in vivo peak tibial strain
VEH ED-L ED-M ED-H
Force (N) 37.5 ± 0.43 37.7 ± 0.4 37.7 ± 0.22 37.2 ± 0.32
Moment of inertia (mm4) 1.82 ± 0.22 1.95 ± 0.31 1.81 ± 0.20 1.77 ± 0.25
Compressive peak strain (μstrain) 2240.2 ± 225.8 2127.7 ± 256.9 2182.0 ± 199.2 2283.0 ± 278.1
Compressive peak strain was calculated using beam-bending theory based on each moment of inertia. ED-H: high dose eldecalcitol; ED-M: medium dose eldecalcitol,
ED-L; low dose eldecalcitol; VEH: vehicle
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the VEH group and the other three groups. There were
no significant differences in final body weights between
the VEH group and the other three groups, however;
there were significant differences between initial and
final body weight values in the ED-H (P < 0.001) and
ED-M (P < 0.001) groups.
Applied force and in vivo strain
The monitored mean applied force during loading was
37.5 ± 0.4 N. The applied force, moment of inertia, and
in vivo peak tibial strain are shown in Table 1. There
were no significant differences in these values among
the four groups. The variation between strains within
each group was due to differences in the tibial moment
of inertia in each rat.
Histomorphometry
Increased bone formation was observed in cross-
sections of loaded tibiae, as greater calcein labeling oc-
curred on both the periosteal and endocortical surfaces
than in the non-loaded tibiae (Fig. 2). In three rats in the
VEH group, woven bone formation was observed at the
lateral and medial periosteal surfaces of the loaded
(right) tibiae; however, no woven bone was observed in
the ED groups.
Cortical area
There were no significant differences in Ct.Ar, TtT.Ar,
or Ma.Ar between the loaded and non-loaded tibiae
(Table 2). There were no significant differences among
the four groups in the loaded and non-loaded tibiae.Fig. 2 Cross-sections of high-dose eldecalcitol rat. (a) Left tibia; (b) right tib
compared with the left (non-loaded) tibia, indicated by increased calcein laLateral periosteal surface
There were significant differences in F.Pm, MAR, and
BFR between the loaded and non-loaded sites (P < 0.001
by repeated two-way ANOVA) (Fig. 3). F.Pm and BFR
were highest in the ED-H group among the four groups
at the loaded tibiae; however, the differences were not
statistically significant by Dunnett’s test.
Medial periosteal surface
There were significant differences between the loaded
and non-loaded sites in F.Pm, MAR, and BFR (P < 0.001
by repeated two-way ANOVA) (Fig. 4). F.Pm, MAR, and
BFR were highest in the ED-H group among the four
groups at both loaded and non-loaded tibiae; however,
the differences were not statistically significant by Dun-
nett’s test.
Endocortical surface
There was a significant effect of external loading on
F.Pm, MAR, and BFR (P < 0.001 by repeated two-way
ANOVA) (Fig. 5). F.Pm and MAR were highest in the
ED-H group among the four groups at both loaded and
non-loaded tibiae; however, the differences were not sta-
tistically significant. BFR was significantly higher in the
ED-H group compared with the VEH group (P = 0.019,
by Dunnett’s test), and the interaction between loading
and eldecalcitol treatment was significant (P = 0.043).
Discussion
Mechanical loading accelerates bone formation by
stimulating osteoblasts and their precursors via a signal
network of osteocytes and osteoblasts. Recent studies onia. Increased bone formation was observed in the right (loaded) tibia
beling at both the periosteal and endocortical surfaces
Table 2 Cortical area measurements
VEH ED-L ED-M ED-H
TtT.Ar (mm2) loaded 5.6 ± 0.3 5.8 ± 0.3 5.8 ± 0.3 5.5 ± 0.4
non-loaded 5.6 ± 0.2 5.6 ± 0.2 5.7 ± 0.4 5.5 ± 0.4
Ma.Ar (mm2) loaded 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.2 1.7 ± 0.3
non-loaded 1.8 ± 0.2 1.7 ± 0.2 1.9 ± 0.2 1.7 ± 0.2
Ct.Ar (mm2) loaded 3.9 ± 0.2 4.0 ± 0.2 3.8 ± 0.2 3.8 ± 0.4
non-loaded 3.8 ± 0.1 4.0 ± 0.3 4.0 ± 0.3 3.7 ± 0.3
ED-H: high dose eldecalcitol; ED-M: medium dose eldecalcitol, ED-L; low dose
eldecalcitol; VEH: vehicle
Fig. 3 Bone response at the lateral periosteal surface. (a) Formation
perimeter (F.Pm); (b) mineral apposition rate (MAR); (c) bone formation
rate (BFR). There were significant differences between the loaded and
non-loaded sites in all three parameters by repeated two-way analysis
of variance (P < 0.001). F.Pm and BFR in the high-dose eldecalcitol
group were highest among the four groups at the loaded tibiae;
however, the differences with the vehicle group were not significant
compared by Dunnett’s test. Data are mean ± SEM. ED-H: high dose
eldecalcitol; ED-M: medium dose eldecalcitol, ED-L; low dose
eldecalcitol; VEH: vehicle
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to shed light on the mechanisms underlying the control
of bone mass by loading [20]. Devices for four-point
bending of the tibia [11] and for loading of the ulna in
the axial direction [21] have been developed to quantita-
tively measure the degree of strain in bone caused by
non-invasive mechanical loading, as well examining the
effects of duration and frequency of stress on bone for-
mation. A previous study used a four-point bending de-
vice with a loading schedule of 36 cycles at 2 Hz, 3 days
per week (the same parameters used in the current ex-
periment), and demonstrated increased bone formation
[13]. Consistent with previous work, we observed cor-
tical bone response at both the periosteal and endocorti-
cal surfaces [22, 23]. Ours is the first study to evaluate
bone response during the simultaneous administration
of eldecalcitol and mechanical stimulation. It is also the
first to analyze the effects of eldecalcitol at three differ-
ent doses. In this study, eldecalcitol dose-dependently
enhanced bone formation and this enhancement showed
interaction with bending effects in BFR at the endocorti-
cal surface.
In a preventive study in which eldecalcitol was admin-
istered orally once daily at dosages of 0.05 μg/kg, 0.1 μg/
kg, and 0.2 μg/kg, dose-dependent improvements oc-
curred in bone mineral density and mechanical proper-
ties in an ovariectomized rat model [8]. Based on this
model, we used 0.025 μg/kg, 0.05 μg/kg, and 0.1 μg/kg
of eldecalcitol 3 days per week. In Japan, eldecalcitol has
been approved to treat involutional osteoporosis at a
daily dose of 0.75 μg [24]. In this study, the eldecalcitol
doses in rats ranged from 0.05 μg/kg to 0.1 μg/kg, both
3 days per week, and were between 3.9- and 15.5-fold
higher than the 0.75-μg daily dose administered to a hu-
man weighing 50 kg.
We demonstrated that eldecalcitol enhanced bone for-
mation dose-dependently and exerted a synergistic effect
on the cortical bone response to mechanical loading at
the endocortical surface. Active vitamin D compounds
induce receptor-activated of NF-κB ligand (RANKL) ex-
pression in osteoblastic cells and enhance osteoclast for-
mation and bone resorption in vitro [25]. It has beenreported that mice with global VDR knockout as well as
those with conditional knockout of VDR in osteoblasts
show a higher bone mass with reduced bone resorption;
Fig. 4 Bone response at the medial periosteal surface. (a) Formation
perimeter (F.Pm); (b) mineral apposition rate (MAR); (c) bone formation
rate (BFR). There were significant differences between the loaded
and non-loaded sites in all three parameters by repeated two-
way analysis of variance (P < 0.001). F.Pm, MAR, and BFR in the
high-dose eldecalcitol (ED-H) group were highest among the
four groups at both loaded and non-loaded tibiae; however, the
differences with the vehicle group were not significant compared
by Dunnett’s test. Data are mean ± SEM. ED-H: high dose eldecalcitol;
ED-M: medium dose eldecalcitol, ED-L; low dose eldecalcitol;
VEH: vehicle


































Fig. 5 Bone response at the endocortical surface. (a) Formation
perimeter (F.Pm); (b) mineral apposition rate (MAR); (c) bone
formation rate (BFR). External loading exerted a significant effect
on all three parameters (P < 0.001 by repeated two-way analysis of
variance). F.Pm and MAR in the high-dose eldecalcitol (ED-H)
group were highest among the four groups at both loaded and
non-loaded tibiae; however, the differences with the vehicle (VEH)
group were not significant compared by Dunnett’s test. BFR in the
ED-H group was significantly higher than in the VEH group (P = 0.019,
by Dunnett’s test), and the interaction between loading and the effects
of eldecalcitol was significant (P = 0.043 by repeated two-way analysis
of variance). Data are mean ± SEM. ED-H: high dose eldecalcitol; ED-M:
medium dose eldecalcitol, ED-L; low dose eldecalcitol; VEH: vehicle
Yamasaki et al. BMC Musculoskeletal Disorders  (2015) 16:158 Page 6 of 8
Yamasaki et al. BMC Musculoskeletal Disorders  (2015) 16:158 Page 7 of 8however, bone histomorphometry showed no effect on
bone formation parameters [26]. It was reported that
eldecalcitol suppressed bone resorption by reducing the
number of RANKL-positive cells on the trabecular bone
surface [6]. The decrease in bone formation following
low-dose eldecalcitol administration is thought to be the
result of a coupling reaction induced by the suppression
of bone resorption; however, this reaction may be offset
by the positive effects of high-dose eldecalcitol on bone
formation in response to mechanical loading.
Prior research showed that eldecalcitol administration
for 12 weeks increased cancellous bone volume and
bone formation rate without affecting bone resorption in
aged rats [7]. We previously demonstrated in a rabbit
model that distraction osteogenesis with eldecalcitol in-
creased callus volume during the early period after the
completion of lengthening, resulting in thick cortical
bone formation [27]. In a rabbit model examining ex-
pansion of the mid-palatal suture, eldecalcitol had posi-
tive effects on bone formation parameters in the early
phase of bone regeneration [28]. One research group re-
ported that eldecalcitol reduced osteoclast numbers and
diminished osteoclastic activity and function, without
promoting osteoclast apoptosis in ovariectomized rats
[29, 30]. This group also demonstrated “bud-like” or
“bouton-like” bone formation patterns characteristic of
bone minimodeling in eldecalcitol-treated ovariecto-
mized rats at rates 10-fold higher than in those treated
with calcitriol, and suggested that eldecalcitol stimulates
osteoblastic activity at the bone surface in vivo. Bone
formation in response to mechanical loading is primarily
due to modeling of cortical bone. Increased bone forma-
tion in the current study suggests that bone modeling of
cortical bone could be increased by eldecalcitol treat-
ment. These data demonstrate that eldecalcitol was cap-
able of increasing bone mass not only by suppressing
bone resorption, but also by stimulating bone formation.
Eldecalcitol increased bone formation at the periosteal
surface of SAM/P6 mice, and it is speculated that elde-
calcitol activates Wnt signaling and/or growth factor sig-
naling via enhanced muscle function [31]. In the current
study it is possible that eldecalcitol suppressed sclerostin
expression and activated Wnt signaling caused by mech-
anical loading. However, the effect of eldecalcitol on
sclerostin is still unclear. Two clinical observations re-
ported conflicting results regarding sclerostin changes
after treatment with vitamin D [32, 33], and therefore
further studies are required to clarify this phenomenon.
We observed a significant increase in bone formation
at the endocortical surface. Since the direct effects of
the loading pads affect the response at the periosteal
surface and woven bone influenced periosteal surfaces,
the values of F.Pm were not increased in a dose-
dependent manner, which is consistent with previousstudies [22, 23]. Compared to the periosteal surface,
the preferential endocortical bone response to loading
and to eldecalcitol treatment may be due to the lack of
a direct pad effect and to the lower induced mechanical
strain (stimulus).
There are several limitations to this study. First, the ex-
periments were performed on rats rather than humans.
Unlike humans, rat cortical bone has no Haversian system,
so cortical bone remodeling is absent. Second, the rats in
the model we used were estrogen-replete, and the effects
at estrogen-deplete status have not been defined.
Conclusions
This study used a rat model to assess the interactions be-
tween eldecalcitol administration and mechanical loading
of cortical bone. Eldecalcitol enhanced the cortical bone re-
sponse to mechanical loading through a synergistic effect.
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